



7 May 2020

**EKF Diagnostics Holdings plc**  
("EKF" or the "Company")

**Posting of Annual Report & Accounts and Notice of AGM**

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, confirms that the Annual Report and Accounts for the year ended 31 December 2019 ("2019 Annual Report") and the Notice of the Annual General Meeting contained therein (the "Notice of AGM") are available on the Company's website:

<https://www.ekfdiagnostics.com/documents-reports.html>

The 2019 Annual Report, the Notice of AGM and details voting by proxy will be posted to shareholders who have not consented to receive electronic communications today, 7 May 2020.

The AGM is to be held on 10 June 2020 at 11am at the Company's offices at Avon House, 19 Stanwell Road, Penarth, Cardiff CF64 2EZ and will consider the Resolutions set out in the Notice of AGM, including the proposed resolution to declare a final dividend of 1p per ordinary share to be paid on 1 December 2020 to shareholders on the register at the close of business on 5 November 2020.

In light of the current UK Government's public health advice in response to the COVID-19 outbreak, including to limit travel and public gatherings, and the likelihood that this advice may remain in place at the time of the AGM, the Company requests that no Shareholders should plan to attend the AGM in person.

Only two members appointed by the Board will attend in person, one of whom will Chair the meeting. These Shareholders will constitute the minimum quorum for the AGM to take place under the Company's Articles of Association and the requirements of the Companies Act 2006. The Company is not facilitating any arrangements for a physical meeting for any Shareholders on this day (other than the two members referred to above) other than online or telephonic participation.

Shareholders wishing to vote on any of the matters of business are urged to do so through completion of their form of proxy, which can be submitted to the Company's Registrar online. Forms of proxy should be completed and submitted online in accordance with the instructions thereon.

The Company will provide a facility for shareholders to join the AGM either online or telephonically and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Board would request that Shareholders register for the meeting and submit questions in advance, before 5pm (BST) on 8 June 2020.

To register for dial-in details and to submit any questions please contact Walbrook PR via email at [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com) or call +44 (0)20 7933 8787.

**Enquiries:**

**EKF Diagnostics Holdings plc**

Christopher Mills, Non-Executive Chairman  
Julian Baines, CEO  
Richard Evans, FD & COO

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)

**Tel: 029 2071 0570**

**N+1 Singer (Nomad & Broker)**

Aubrey Powell / George Tzimas / Carlo Spingardi (Corporate Finance)  
Tom Salvesen (Corporate Broking)

**Tel: 020 7496 3000**

**Walbrook PR Limited**

Paul McManus/ Lianne Cawthorne

**Tel: 020 7933 8780 or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)**

**Mob: 07980 541 893 / 07584 391 303**

**About EKF Diagnostics Holdings plc ([www.ekfdiagnostics.com](http://www.ekfdiagnostics.com))**

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a as well as providing Central Laboratory & Lifesciences services in the area of clinical chemistry, small lab analysers, contract fermentation, enzyme manufacturing and specialised contract manufacturing.